BGD.WAR Biogened

Healthcare Oil, Gas & Consumable Fuels Warsaw Stock Exchange
18.90 PLN
Close of Oct 29, 2026
16.84 24.92
Market cap
PLN 46.4M
P/E
9.6x
P/B
0.97x
ROE
16.5%
Dividend yield
2.65%
Fundamental score
2.9/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BGD.WAR undervalued?

Graham number
Price18.90
Graham value29.27
Discount35.4%

BGD.WAR trades 35.4% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biogened fundamental analysis

15 of 22 checks passed

ROE 1/2

Moderate return on equity (16.5%), between 10% and 20%.

ROA 1/1

Return on assets (8.1%) is above the industry median (3.0%).

Profit Consistency 1/2

Profitable for 4 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-15.1%) is below the industry median (16.0%).

Revenue Growth 2/2

Revenue grew 12.4% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (47.2%), up to 100%.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 7.2x against interest expense, well covered.

PE vs Market 1/1

PE (9.6x) is below the market median (11.6x).

PE vs Industry 1/1

PE (9.6x) is below the industry median (9.9x).

PBV 1/1

Price to book (1.0x) is below the industry median (2.8x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 9.4, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (2.6%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 24.9%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Biogened stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biogened

Biogened S.A. produces and sells cosmetics and toiletries in Poland. The company offers dermo-cosmetics under the Dermedic brand, as well as thermal water. It also exports its products. The company was incorporated in 2007 and is headquartered in Lódz, Poland.

Full company profile